Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190928 | 0.81 | CYP1A2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL8947886 | 0.79 | LMNA (0.55) | CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL191353 | 0.79 | LMNA (0.55) | CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL18711893 | 0.79 | CYP1A2 (0.46) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL12036175 | 0.79 | CYP1A2 (0.46) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL27392467 | 0.78 | NOS2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL11850495 | 0.78 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL14627318 | 0.77 | CYP1A2 (0.44) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL18812726 | 0.77 | CYP1A2 (0.44) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL1835887 | 0.77 | LMNA (0.53) | CYP1A2TDP1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439174-B1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | CYP1A2 210/4885TDP1 3986/4885EPHX2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.